Lineage Announces Exclusive Option Agreement With Amasa Therapeutics for Supply and Use of Clinical-Grade Hystem®
Retrieved on:
Thursday, June 17, 2021
Research, Public relations, Investor relations, Communications, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Life sciences, Biology, Biotechnology, Stem cells, Cell biology, Cell therapy, Biopharmaceutical, Bioactive, HyStem®, Amasa Therapeutics, Inc., Lineage Cell Therapeutics, Inc., HYSTEM®, AMASA THERAPEUTICS, INC., LINEAGE CELL THERAPEUTICS, INC.
Under the option agreement, Amasa will purchase certain amounts of Lineages existing supply of clinical-grade HyStem biomaterial and has the right to purchase additional amounts in connection with its up to 12-month option to acquire the exclusive license.
Key Points:
- Under the option agreement, Amasa will purchase certain amounts of Lineages existing supply of clinical-grade HyStem biomaterial and has the right to purchase additional amounts in connection with its up to 12-month option to acquire the exclusive license.
- From this portfolio, we continue to find opportunities to unlock value from non-core assets through option and license agreements for assets such as HyStem, stated Brian Culley, Lineage CEO.
- Building upon this technology, the HyStem family of hydrogels are novel biomaterials that offer unique strategies for cell therapy and bioactive molecule delivery.
- Amasa Therapeutics is a biopharmaceutical company focused on the development of novel stem cell-based targeted biological therapeutics to treat cancer patients with unmet need.